Get started
Biogen Inc.Biogen Inc.Biogen Inc.

Biogen Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

BIIB chart

Key stats

Market capitalization
‪28.61 B‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
24.83
Basic EPS (TTM)
8.03USD
Net income
‪1.16 B‬USD
Revenue
‪9.42 B‬USD
Shares float
‪144.19 M‬
Beta (1Y)
0.74

About Biogen Inc.

Sector
Health Technology
CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
biogen.com
Employees (FY)
‪7.57 K‬
Founded
1978
ISIN
US09062X1037
FIGI
BBG000C17X76
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Sparks

Curated watchlists where BIIB is featured.

See all sparks 

Frequently Asked Questions

The current price of BIIB is 195.26 USD — it has decreased by 0.78% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Biogen Inc. stocks are traded under the ticker BIIB.
Biogen Inc. is going to release the next earnings report on Apr 24, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Biogen Inc. has a max estimate of 393.00 USD and a min estimate of 215.00 USD.
BIIB earnings for the last quarter are 4.36 USD whereas the estimation was 3.97 USD which accounts for 9.73% surprise. Estimated earnings for the next quarter are 3.18 USD. See more details about Biogen Inc. earnings.
Biogen Inc. revenue for the last quarter amounts to ‪2.53 B‬ USD despite the estimated figure of ‪2.40 B‬ USD. In the next quarter revenue is expected to reach ‪2.47 B‬ USD.
Yes, you can track Biogen Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, BIIB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Biogen Inc. stock right from TradingView charts — choose your broker and connect to your account.
BIIB reached its all-time high on Jun 7, 2021 with the price of 468.55 USD, and its all-time low was 0.33 USD and was reached on Dec 14, 1994.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has ‪7.57 K‬ employees. See our rating of the largest employees — is Biogen Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Biogen Inc. EBITDA is ‪2.13 B‬ USD, and current EBITDA margin is 22.58%. See more stats in Biogen Inc. financial statements.